E
Eikon Therapeutics
Biotech & Life Sciences · Hayward, United States · Founded 2019 · IPO 2026
Investors
24 investors on Eikon Therapeutics's cap table
Sourced from Dealroom's funding history. Investor profile links are shown where available.
Ownership
Who owns Eikon Therapeutics
Share of equity by holder, from Dealroom's shareholder data. Stakes as last recorded by Dealroom (May/2026).
Global footprint
Where Eikon Therapeutics has talent and traffic
team presence
across markets
Talent graph
The shape of Eikon Therapeutics's talent
Dealroom maps Eikon Therapeutics's team person by person — pinpointing the standout operators and scoring them across the six dimensions investors underwrite. The counts and shape below are a public preview; the named individuals and exact scores live in the platform.
Source: Dealroom Talent Intelligence. Public profiles show counts and the team's shape only — request a demo for the named individuals, per-person seniority and tenure, and team benchmarks vs peers.
Patent intelligence
$36M patent portfolio · 58 active families
Where Eikon Therapeutics concentrates vs peers
Each axis is a top-10 topic across Eikon Therapeutics and its closest peers. #1 = 100, #10 = 10, absent = 0.
Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.
Market sentiment
What the market is saying about Eikon Therapeutics
An AI-synthesized read of the highest-engagement posts about Eikon Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Eikon Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.